Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19. | Turk J Biol | 2022 | 37533516 | PubTator, text mining | PubMed |
| Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions. | Front Radiol | 2022 | 37492687 | PubTator, text mining | PubMed |
| Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. | Exploration (Beijing) | 2022 | 37323702 | PubTator, text mining | PubMed |
| The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world. | Blood Cell Ther | 2022 | 37220608 | PubTator, text mining | PubMed |
| Current advances of CRISPR-Cas technology in cell therapy. | Cell Insight | 2022 | 37193354 | PubTator, text mining | PubMed |
| Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges. | Front Immunol | 2022 | 36969979 | PubTator, text mining | PubMed |
| A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination. | Cancer Res Commun | 2022 | 36923303 | PubTator, text mining | PubMed |
| Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform. | Cancer Res Commun | 2022 | 36874404 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity. | Cancer Res Commun | 2022 | 36860694 | PubTator, text mining | PubMed |
| Scientific Basics of Personalized Medicine: Realities and Opportunities. | Her Russ Acad Sci | 2022 | 36744158 | PubTator, text mining | PubMed |
| Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. | Front Oncol | 2022 | 36741695 | PubTator, text mining | PubMed |
| Optimizing Blood Stem Cell Transplants Through Cellular Engineering. | Blood Cell Ther | 2022 | 36714264 | PubTator, text mining | PubMed |
| Harnessing the immune system in the treatment of cutaneous T cell lymphomas. | Front Oncol | 2022 | 36713518 | PubTator, text mining | PubMed |
| Cancer organoid co-culture model system: Novel approach to guide precision medicine. | Front Immunol | 2022 | 36713421 | PubTator, text mining | PubMed |
| [Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709176 | PubTator, text mining | PubMed |
| Macrophages as a Potential Immunotherapeutic Target in Solid Cancers. | Vaccines (Basel) | 2022 | 36679900 | PubTator, text mining | PubMed |
| Advances in adoptive cellular therapy for colorectal cancer: a narrative review. | Ann Transl Med | 2022 | 36660664 | PubTator, text mining | PubMed |
| Ferroptosis-related genes with post-transcriptional regulation mechanisms in hepatocellular carcinoma determined by bioinformatics and experimental validation. | Ann Transl Med | 2022 | 36660631 | PubTator, text mining | PubMed |
| New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme. | Explor Target Antitumor Ther | 2022 | 36654821 | PubTator, text mining | PubMed |
| Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis. | Front Oncol | 2022 | 36644638 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=46